The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity

GNF‐2 may have potential for the treatment of inflammatory bone destruction characterized by increased osteoclast number and/or activity. GNF‐2, a tyrosine kinase inhibitor, was developed to overcome imatinib‐resistant mutations found in CML patients. Osteoclasts are the principal bone‐resorbing cel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of leukocyte biology 2014-02, Vol.95 (2), p.337-345
Hauptverfasser:	Kim, Hyun‐Ju, Yoon, Hye‐Jin, Choi, Je‐Yong, Lee, In‐Kyu, Kim, Shin‐Yoon
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Benzamides - pharmacology Bone and Bones - drug effects Bone and Bones - pathology Bone Marrow Cells - pathology Bone Resorption - pathology Cell Proliferation - drug effects Cell Survival - drug effects Cell Survival - genetics Cytoskeleton - drug effects Cytoskeleton - metabolism c‐Fms c‐Fos Imatinib Mesylate Inflammation - pathology LPS Macrophages - drug effects Macrophages - metabolism Macrophages - pathology Mice Mice, Inbred C57BL NF-kappa B - metabolism NFATC Transcription Factors - metabolism NF‐κB Osteoclasts - drug effects Osteoclasts - enzymology Osteoclasts - pathology osteoporosis Piperazines - pharmacology Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins c-fos - metabolism Pyrimidines - pharmacology RANK Ligand - pharmacology Receptor, Macrophage Colony-Stimulating Factor - metabolism Signal Transduction - drug effects Signal Transduction - genetics Transcription, Genetic - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!